Clinical trial · Interventional
Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery
NCT02617264CI-TRIAL-00020009unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess feasibility and clinical utility of marking biopsied axillary lymph nodes with Spot at time of biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SPOT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Axillary lymph node FNA Biopsy
- description
- A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
- interventionNames
- Procedure: SPOT
Primary outcomes (1)
- measure
- Intra operative identification the Spot TM marked node at the time of surgery
- timeFrame
- Within 1 year of enrollment
Secondary outcomes (1)
- measure
- Correlation between Spot TM marked lymph node and sentinel lymph node
- timeFrame
- Within 1 year of enrollment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Women with findings suspicious of breast cancer (or known breast cancer) who undergo axillary lymph node biopsy Exclusion Criteria: * Inability to sign Informed Consent
References
Publications (0)
Data not yet available
No reference posted for this study.